Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
- PMID: 35294525
- DOI: 10.1158/0008-5472.CAN-21-2931
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
Abstract
CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression in normal tissue, making it an attractive CAR T target for an immunogenic solid tumor indication. Here we generated and characterized a panel of anti-CD70 single-chain fragment variable (scFv)-based CAR T cells. Despite the expression of CD70 on T cells, production of CAR T cells from a subset of scFvs with potent in vitro activity was achieved. Expression of CD70 CARs masked CD70 detection in cis and provided protection from CD70 CAR T cell-mediated fratricide. Two distinct classes of CAR T cells were identified with differing memory phenotype, activation status, and cytotoxic activity. Epitope mapping revealed that the two classes of CARs bind unique regions of CD70. CD70 CAR T cells displayed robust antitumor activity against RCC cell lines and patient-derived xenograft mouse models. Tissue cross-reactivity studies identified membrane staining in lymphocytes, thus matching the known expression pattern of CD70. In a cynomolgus monkey CD3-CD70 bispecific toxicity study, expected findings related to T-cell activation and elimination of CD70-expressing cells were observed, including cytokine release and loss of cellularity in lymphoid tissues. Finally, highly functional CD70 allogeneic CAR T cells were produced at large scale through elimination of the T-cell receptor by TALEN-based gene editing. Taken together, these efficacy and safety data support the evaluation of CD70 CAR T cells for the treatment of RCC and has led to the advancement of an allogeneic CD70 CAR T-cell candidate into phase I clinical trials.
Significance: These findings demonstrate the efficacy and safety of fratricide-resistant, allogeneic anti-CD70 CAR T cells targeting renal cell carcinoma and the impact of CAR epitope on functional activity. See related commentary by Adotévi and Galaine, p. 2517.
©2022 American Association for Cancer Research.
Comment in
-
Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen.Cancer Res. 2022 Jul 18;82(14):2517-2519. doi: 10.1158/0008-5472.CAN-22-1739. Cancer Res. 2022. PMID: 35844172
Similar articles
-
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.J Transl Med. 2024 Apr 18;22(1):368. doi: 10.1186/s12967-024-05101-1. J Transl Med. 2024. PMID: 38637886 Free PMC article.
-
Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen.Cancer Res. 2022 Jul 18;82(14):2517-2519. doi: 10.1158/0008-5472.CAN-22-1739. Cancer Res. 2022. PMID: 35844172
-
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.Theranostics. 2020 Jun 18;10(17):7622-7634. doi: 10.7150/thno.43991. eCollection 2020. Theranostics. 2020. PMID: 32685008 Free PMC article.
-
Evolution of cell therapy for renal cell carcinoma.Mol Cancer. 2024 Jan 9;23(1):8. doi: 10.1186/s12943-023-01911-x. Mol Cancer. 2024. PMID: 38195534 Free PMC article. Review.
-
Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma.J Immunol. 2023 Oct 1;211(7):1067-1072. doi: 10.4049/jimmunol.2200591. J Immunol. 2023. PMID: 37722095 Review.
Cited by
-
Letter to the editor for the article " Causal associations of immune cells with benign prostatic hyperplasia: insights from a Mendelian randomization study".World J Urol. 2024 May 29;42(1):358. doi: 10.1007/s00345-024-05064-4. World J Urol. 2024. PMID: 38811398 No abstract available.
-
Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors.Cell Death Dis. 2024 May 24;15(5):359. doi: 10.1038/s41419-024-06734-2. Cell Death Dis. 2024. PMID: 38789450 Free PMC article. Review.
-
CAR-T Cell Therapy: Advances in Kidney-Related Diseases.Kidney Dis (Basel). 2024 Jan 10;10(2):143-152. doi: 10.1159/000536194. eCollection 2024 Apr. Kidney Dis (Basel). 2024. PMID: 38751795 Free PMC article. Review.
-
CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.Front Immunol. 2024 Apr 12;15:1385571. doi: 10.3389/fimmu.2024.1385571. eCollection 2024. Front Immunol. 2024. PMID: 38680498 Free PMC article. Review.
-
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.J Transl Med. 2024 Apr 18;22(1):368. doi: 10.1186/s12967-024-05101-1. J Transl Med. 2024. PMID: 38637886 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials